



ISSN Print: 2394-7500
 ISSN Online: 2394-5869
 Impact Factor: 3.4
 IJAR 2015; 1(6): 276-281
 www.allresearchjournal.com
 Received: 22-03-2015
 Accepted: 29-04-2015

Shabeer Sakkeena Iqbal
 Department of Clinical
 Biochemistry, Frontier Lifeline
 Hospital and Dr. K. M. Cherian
 Heart Foundation, Mogappair,
 Chennai – 600101, India.

Prema Gurumurthy
 Director-Research, MAHER
 Meenakshi University, Chennai,
 India.

Patchaiappan Pravinkumar
 Department of Toxicology,
 Frontier Lifeline Hospital and
 Dr. K. M. Cherian Heart
 Foundation, Mogappair,
 Chennai– 600101, India.

Pawankumar
 Department of Toxicology,
 Frontier Lifeline Hospital and
 Dr. K. M. Cherian Heart
 Foundation, Mogappair,
 Chennai– 600101, India.

Kalathil Sadasivan Pillai
 Department of Toxicology,
 Frontier Lifeline Hospital and
 Dr. K. M. Cherian Heart
 Foundation, Mogappair,
 Chennai– 600101, India.

Correspondence:

Prema Gurumurthy
 Director-Research, MAHER
 Meenakshi University, Chennai,
 India.

GC-MS analysis, heavy metal content and predication of anti-diabetic activity spectra of a novel polyherbal formulation

Shabeer Sakkeena Iqbal, Prema Gurumurthy, Patchaiappan Pravinkumar, Pawankumar, Kalathil Sadasivan Pillai

Abstract

Since there is a very huge development in the use of traditional medicine, assurance and potency as well as quality control of herbal medicines and traditional therapies are became more important. Hence, to determine the active principle compounds and its possible biological and pharmacological activities of a novel polyherbal formulation by using GC-MS and PASS (Prediction Activity Spectra for Substances) were carried out. Polyherbal formulation (PHF) was made up of four plants namely *Syzygium cumini*, *Picrorhiza kurroa*, *Madhuca indica* and *Commiphoramukul*. Methanol extract of PHF was used as the sample for GC-MS analysis. The identified compounds by GC-MS are Corynan-17-ol -18,19-didehydro-10-methoxy-, acetate (ester), Hexadecanoic acid methyl ester, 8-octa decenoic acid methyl ester, Octadecanoic acid methyl ester, Carda-4, 20(22)-di enolide and 4-Chlorocholest-4-en-3-one. The biological activities of the identified compounds are predicted with the help of Prediction Activity Spectra for Substances technique. The heavy metal analysis carried out by atomic emission spectroscopy method. The result showed that the PHF not contains high toxic level of heavy metals; (Arsenic -0.022 mg/L; below detectable level, Chromium 0.026 mg/L and Lead 0.006 mg/L; below detectable level).

Keywords: Anti-diabetic, *Commiphora mukul*, Gas chromatography, Heavy Metal, *Madhuca indica*, PASS, *Picrorhiza kurroa*, *Syzygium cumini*

Abbreviations

PASS- Prediction Activity Spectra for Substances

PFK- Perfluorokerosene

PHF- Polyherbal formulation

SAR- Structure-Activity Relationships

1. Introduction

For the last few years, there has been a global trend for the regeneration of awareness in the traditional system of treatments because of the various side effects/ toxic effects of synthetic compounds. So investigation of medicinal plants using indigenous medical systems has become ever more important for speed up better and effective treatment, especially in the case of Diabetes mellitus. Since there is a very huge development in the use of traditional medicine, assurance and potency as well as quality control of herbal medicines and traditional therapies are became more important concerns for both health authorities and the public in all over the world [Kadir MF *et al.*, 2013] [5]. Essential products from medicinal plants, both as isolated compounds or as extracts/formulations, provide unrestricted opportunities for new drug leads [Murugesan A *et al.*, 2014] [9].

Heavy metals are widespread in soil as a result of geo-climatic conditions and environmental pollution. Therefore, their assimilation and accumulation in plants is common (Kofi Annan *et al.*, 2010) [6]. The heavy metal content in the plant was beneficial only to a certain limit. The heavy metal stress in the plant affects the entire cycle of life due their accumulation in the biological species and further bio magnifications to the higher order levels thereby accumulating as much of metal stressors in the environment (Mohammad *et al.*, 2012) [8]. Heavy metals cause stress to the cells in the body and hence affects the oxidation process called as the oxidative damage. In the present study, the concentration of various toxic heavy metallic elements in the PHF were analyzed using Inductively coupled plasma atomic emission spectroscopy (ICP-AES) - Ferkin Elmer Optima 5300 DV.

The diverse and complex chemical structures of compounds provide the basis for modulation of different targets. Since there are thousands of known pharmacological targets are present, studying and understanding of these targets and their mechanisms will be very difficult and hectic job. So a computer aided method could be extremely useful for this purpose. Hence, to determine the active principle compounds and its possible biological and pharmacological activities of a novel anti-diabetic polyherbal formulation by using GC-MS and PASS (Prediction Activity Spectra for Substances) were carried out.

2. Materials and Methods

Polyherbal formulation (PHF)

Polyherbal formulation (PHF) is made up of four plants namely *Syzygium cumini*, *Picrorhiza kurroa*, *Madhucaindica* and *Commiphora mukul*

2.1 Heavy metal analysis

Inductively coupled plasma atomic emission spectroscopy (ICP-AES), also referred to as inductively coupled plasma optical emission spectrometry (ICP-OES), is an analytical technique used for the detection of trace metals. It is a type of emission spectroscopy that uses the inductively coupled plasma to produce excited atoms and ions that emit electromagnetic radiation at wavelengths characteristic of a particular element. The intensity of this emission is indicative of the concentration of the element within the sample. Emission spectrometry is based on the principle that atoms or ions in an excited state tend, to revert back to the ground state and in so doing emit characteristic wavelength and intensity of that light is proportional to the concentration of that particular element in the sample solution. This technique is used for quantitative and quality determination of the metals and metalloids in the sample.

2.2 Gas Chromatography-Mass spectrometry (GC-MS)

Methanol extract of PHF was used as the sample for GC-MS analysis. The solution (μl) was injected with the help of a micro syringe into injection port of GC system. Chromatographic separation was carried out with JEOL GCMATE II GC-MASS SPECTRO METER; it is a combination of Agilent technologies (Gas chromatographic system) and Jeol GC mate II (Mass spectrometry). Gas chromatographic system has HP-5 column to program temperature of maximum 250°C . High pure Helium is carrier gas. A typical Mass spectrometer consists of Tungsten filament as electron source which works with 70eV, a double focusing analyzer and photo multiplier tube as detector with resolution of maximum 5000. The precise mass is determined by comparing the unknown mass of the sample peak with the known mass of a reference peak. The reference sample used here: Perfluorokerosene (PFK) for calibration.

2.3 Identification of components

Interpretation of mass spectrum GC-MS was conducted using the database of National Institute Standard and Technique (NIST) having more than 62,000 patterns. The spectrum of the unknown component was compared with the spectrum of the known components stored in the NIST library. The name, molecular weight, structure of the components in the test material was ascertained.

2.4 Prediction Activity Spectra for Substances (PASS)

This computer system can predict biological activity based on structural formula of a chemical compound to reveal novel biological activities of selected compounds, their mechanisms and related side effects. PASS estimates the probabilities of a particular substances belonging to the active and inactive subsets from the SAR Base (Structure-Activity Relationships Base) [4, 10]. Many study reports are available about this approach to predict the various activities of natural products [13, 1].

The PASS can predict several thousand pharmacological effects; biochemical mechanisms of action; specific toxicities; and metabolic terms on the basis of structural formulae of drug like substances with average accuracy. This can be further validated in vitro as well as in vivo assays [2, 10].

2.5 External files of substances

The structure of these chemical compounds were obtained from PubChem (<http://pubchem.ncbi.nlm.nih.gov/>) and Chem Spider (<http://www.chemspider.com/>), and each chemical compound was drawn with chemical drawing tools such as Advanced Chemistry Development (ACD)/Chem Sketch and saved in the ".mol" files ".format. The biological activity spectra of these phyto-constituents were obtained by PASS version (version 9.1, <http://www.ibmc.msk.ru/PASS>).

2.6 Algorithm of prediction

The result of prediction is returned in the form of a table containing the list of biological activity with the appropriate probability values (i.e.) the values defining the likelihood for a given activity type to be either revealed (P_a) or not revealed (P_i) for each activity type from the predicted biological activity spectrum. Their values vary from 0.000 to 1.000. Only those activity types for which $P_a > P_i$ are considered possible. The PASS prediction results were interpreted for the particular compound if (i) $P_a > 0.7$, the chance to find the activity experimentally is high; but the chance of the substance being the analogue of a known pharmaceutical agent is also high (ii) $0.5 < P_a < 0.7$, the chance to find the activity experimentally is less but the compound is probably not so similar to known pharmaceutical agents; and (iii) $P_a < 0.5$, the chance to find the activity experimentally is less, but the chance to find a structurally new compound, that is, new chemical entity is more [12, 7].

3. Results and Discussion

3.1 Heavy metal analysis

Environment, pollution, atmosphere, soil, harvesting and handling are some of the factors, which play a major role in contamination of medicinal plants by metals and also by microbial growth. Therefore it is necessary to measure and establish the levels of metallic elements in the herbal plants as these elements when consumed at higher levels become toxic. The PHF analyzed for the presence of important heavy metals such as Arsenic, Chromium and Lead are analyzed in this study. The result showed that the PHF not contains high toxic level of tested heavy metals. (Table- 1). The heavy metal content did not exceed the limit given according to the WHO guidelines (2007) [14].

Table 1: Heavy Metal Analysis of Polyherbal Formulation

| NO. | COMPOUND | WAVE LENGHT | CONCENTRATION | NORMAL LEVEL |
|-----|---------------|-------------|--------------------|--------------|
| 1 | Arsenic (As) | 188.979 | -0.022 mg/kg (BDL) | 0.053 mg/L |
| 2 | Chromium (Cr) | 267.716 | 0.026 mg/L | 0.007 mg/L |
| 3 | Lead (Pb) | 220.353 | 0.006 mg/L (BDL) | 0.042 mg/L |

BDL- Below Detectable Level

3.2 GCMS

The GC-MS analysis in the methanolic extract of PHF showed the presence of rich variety of phytochemical compounds, are Corynan-17-ol-18,19-didehydro-10-methoxy-, acetate (ester), Hexadecanoic acid methyl ester, 8-octa decenoic acid methyl ester, Octadecanoic acid methyl ester, Carda-4, 20(22)-di enolide and 4-Chlorocholest-4-en-3-one. The active principle compounds, their Molecular weight (MW), Area of Concentration (%), Molecular formula (MF), And Retention Time (RT) are presented (Table 2 and Figures 1-7).

Table: 2- GC MS Analysis of Polyherbal Formulation

| No | Compounds | Retention time(min) | Area of Peak (%) | Molecular formula | Molecular mass |
|----|--|---------------------|------------------|---|----------------|
| 1 | Corynan-17-ol, 18,19-didehydro-10-methoxy-,acetate (ester) | 17.02 | 10.35 | C ₂₂ H ₂₈ N ₂ O ₃ | 368.47 |
| 2 | Hexadecanoic acid, methyl ester (Palmitic Acid) | 17.23 | 16.29 | C ₁₇ H ₃₄ O ₂ | 270.45 |
| 3 | 8-octa decenoic acid, methyl ester | 18.97 | 53.04 | C ₁₉ H ₃₆ O ₂ | 296.40 |
| 4 | Octadecanoic acid, methyl ester (Stearic Acid) | 19.2 | 13.84 | C ₁₇ H ₃₄ O ₂ | 270.45 |
| 5 | Carda-4, 20(22)-di enolide | 23.07 | 3.56 | C ₃₀ H ₄₄ O ₉ | 548.66 |
| 6 | 4-Chlorocholest-4-en-3-one | 26.15 | 2.92 | C ₂₇ H ₄₃ C ₁₀ | 419.08 |




Fig 2: Chromatogram of Corynan-17-ol-18,19-didehydro-10-methoxy-acetate (ester)




Fig 3: Chromatogram of Hexadecanoic acid, methyl ester




Fig 1: Chromatogram obtained from the GC-MS of PHF




Fig 4: Chromatogram of 8-octa decenoic acid, methyl ester




Fig 5: Chromatogram of Octadecanoic acid, methyl ester




Fig 6: Chromatogram of Carda-4, 20(22)-di enolide




Fig 7: Chromatogram of 4-Chlorocholest-4-en-3-one

1. Corynan-17-ol, 18,19-didehydro-10-methoxy-, acetate (ester)

The mass spectrum of the compound showed the molecular ion peak at m/z 368.47, corresponding to the molecular formula C₂₂H₂₈N₂O₃ indicating eight degrees of unsaturation in the molecule

2. Hexadecanoic acid methyl ester

The mass spectrum of the compound showed the molecular ion peak at m/z 270.45, corresponding to the molecular formula C₁₇H₃₄O₂. This compound also known as palmitic acid and it is a saturated fatty acid

3. 8-Octadecenoic acid methyl ester

The mass spectrum of the compound showed the molecular ion peak at m/z 296.49, corresponding to the molecular formula C₁₉H₃₆O₂ indicating two degrees of unsaturation in the molecule.

4. Octadecanoic acid, methyl ester

The mass spectrum of the compound showed the molecular ion peak at m/z 270.45, corresponding to the molecular formula C₁₉H₃₆O₂. This compound also known as stearic acid. It is a saturated fatty acid

5. Carda-4, 20(22)-di enolide and 4-Chlorocholest-4-en-3-one

The mass spectrum of the compound showed the molecular ion peak at m/z 548.66, corresponding to the molecular formula C₃₀H₄₄O₉ indicating four degrees of unsaturation in the molecule

6. 4-Chlorocholest-4-en-3-one

The mass spectrum of the compound showed the molecular ion peak at m/z 419.08, corresponding to the molecular formula C₂₇H₄₃C₁₀ indicating two degrees of unsaturation in the molecule

3.3 PASS

In order to find out the structure and specific activity of the compounds which are identified by GC-MS analysis, it is under gone for prediction of activity by using PASS software. Type of biological activities predicted by PASS includes the pharmacological effects, toxicity, molecular mechanisms and drug likeness of compounds etc. The activities more or less directly related to the diabetes and lipid metabolism are presented in Tables 3-7. Pa and Pi values of each activity was also studied using PASS

Table 3: Prediction of various probable activities of Corynan-17-ol, 18, 19-didehydro-10-methoxy-, acetate (ester)

| No | Pa | Pi | Activity |
|----|-------|-------|---|
| 1 | 0.404 | 0.091 | Lipid metabolism regulator |
| 2 | 0.295 | 0.134 | G-protein-coupled receptor kinase inhibitor |
| 3 | 0.275 | 0.057 | Growth hormone agonist |
| 4 | 0.237 | 0.087 | Antidiabetic symptomatic |
| 5 | 0.192 | 0.018 | Diabetic retinopathy treatment |

Table 4: Prediction of various probable activities of Hexadecanoic acid, methyl ester

| No | Pa | Pi | Activity | No | Pa | Pi | Activity |
|----|-------|-------|---|----|-------|-------|---|
| 1 | 0.914 | 0.003 | Superoxide dismutase inhibitor | 10 | 0.586 | 0.029 | Calcium channel (voltage-sensitive) activator |
| 2 | 0.910 | 0.003 | Lipoprotein lipase inhibitor | 11 | 0.500 | 0.037 | Hypolipemic |
| 3 | 0.894 | 0.005 | G-protein-coupled receptor kinase inhibitor | 11 | 0.466 | 0.004 | Anti-hyperlipoproteinemic |
| 4 | 0.831 | 0.005 | Lipid metabolism regulator | 13 | 0.359 | 0.011 | Pancreatic disorders treatment |
| 5 | 0.822 | 0.010 | Glucose oxidase inhibitor | 14 | 0.330 | 0.012 | Chloride channel activator |
| 6 | 0.753 | 0.004 | Insulin promoter | 15 | 0.283 | 0.009 | HMG CoA synthase inhibitor |
| 7 | 0.723 | 0.007 | Cholesterol antagonist | 16 | 0.323 | 0.070 | Antidiabetic |
| 8 | 0.709 | 0.007 | HMOX1 expression enhancer | 17 | 0.200 | 0.012 | Insulin sensitizer |
| 9 | .632 | 0.010 | Lactase inhibitor | 18 | 0.085 | 0.015 | Lipase inhibitor |

Table 5: Prediction of various probable activities of 8-octa decenoic acid, methyl ester

| No | Pa | Pi | Activity | No | Pa | Pi | Activity |
|----|-------|-------|--|----|-------|-------|---------------------------------|
| 1 | 0.849 | 0.004 | Lipid metabolism regulator | 15 | 0.380 | 0.019 | Free radical scavenger |
| 2 | 0.824 | 0.011 | G-protein-coupled receptor kinase inhibitor | 16 | 0.376 | 0.022 | Lipotropic |
| 3 | 0.815 | 0.005 | Phosphatidylcholine-retinol Oacyltransferase inhibitor | 17 | 0.349 | 0.015 | Cholesterol synthesis inhibitor |
| 4 | 0.789 | 0.005 | Lipoprotein lipase inhibitor | 18 | 0.329 | 0.004 | Diabetic nephropathy treatment |
| 5 | 0.755 | 0.004 | HMOX1 expression enhancer | 19 | 0.340 | 0.022 | Antidiabetic symptomatic |
| 6 | 0.752 | 0.005 | Cholesterol antagonist | 20 | 0.310 | 0.014 | Anti-hyper-lipoproteinemic |
| 7 | 0.728 | 0.005 | Lactase inhibitor | 21 | 0.370 | 0.080 | Insulin promoter |
| 8 | 0.672 | 0.008 | TNF expression inhibitor | 22 | 0.326 | 0.056 | Lipid peroxidase inhibitor |
| 9 | 0.583 | 0.014 | Hepatoprotectant | 23 | 0.269 | 0.030 | Antioxidant |
| 10 | 0.582 | 0.025 | Hypolipemic | 24 | 0.242 | 0.090 | Calcium channel activator |
| 11 | 0.569 | 0.026 | Superoxide dismutase inhibitor | 25 | 0.178 | 0.027 | Antidiabetic (type 1) |
| 12 | 0.571 | 0.035 | Calcium channel activator | 26 | 0.165 | 0.020 | Insulin sensitizer |
| 13 | 0.448 | 0.016 | Cardioprotectant | 27 | 0.157 | 0.013 | Anti-hyper-triglyceridemic |
| 14 | 0.450 | 0.025 | Calcium regulator | | | | |

Table 6: Prediction of various probable activities of Octadecanoic acid

| No | Pa | Pi | Activity | No | Pa | Pi | Activity |
|----|-------|-------|---|----|-------|-------|---------------------------------|
| 1 | 0.750 | 0.008 | Lipoprotein lipase inhibitor | 9 | 0.421 | 0.026 | Diabetic neuropathy treatment |
| 2 | 0.740 | 0.009 | Lipid metabolism regulator | 10 | 0.384 | 0.011 | Cholesterol oxidase inhibitor |
| 3 | 0.738 | 0.010 | Superoxide dismutase inhibitor | 11 | 0.356 | 0.004 | HMGCoA synthase inhibitor |
| 4 | 0.686 | 0.009 | Cholesterol antagonist | 12 | 0.335 | 0.017 | Cholesterol synthesis inhibitor |
| 5 | 0.637 | 0.014 | Calcium channel (voltage-sensitive) activator | 13 | 0.299 | 0.006 | Diabetic nephropathy treatment |
| 6 | 0.492 | 0.023 | Antihyper-cholesterolemic | 14 | 0.186 | 0.014 | Insulin sensitizer |
| 7 | 0.489 | 0.021 | Hepatoprotectant | 15 | 0.104 | 0.009 | Lipase inhibitor |
| 8 | 0.487 | 0.032 | Insulin promoter | | | | |

Table 7: Prediction of various probable activities of Carda-4, 20(22)-enolide

| No | Pa | Pi | Activity | No | Pa | Pi | Activity |
|----|-------|-------|------------------------|----|-------|-------|---------------------------------|
| 1 | 0.627 | 0.016 | Cholesterol antagonist | 5 | 0.289 | 0.025 | Antioxidant |
| 2 | 0.420 | 0.028 | Hepatoprotectant | 6 | 0.238 | 0.037 | Cholesterol synthesis inhibitor |
| 3 | 0.310 | 0.089 | Hypolipemic | 7 | 0.218 | 0.048 | Growth stimulant |
| 4 | 0.292 | 0.015 | | | | | Nitric oxide antagonist |

Table 8: Prediction of various probable activities of 4-Chlorocholest-4-en-3-one

| No | Pa | Pi | Activity | No | Pa | Pi | Activity |
|----|-------|-------|---------------------------------|----|-------|-------|-------------------------------|
| 1 | 0.895 | 0.003 | Cholesterol antagonist | 8 | 0.424 | 0.024 | Diabetic neuropathy treatment |
| 2 | 0.845 | 0.004 | Anti-hypercholesterolemic | 9 | 0.413 | 0.029 | Hepatoprotectant |
| 3 | 0.637 | 0.015 | HMOX1 expression enhancer | 10 | 0.188 | 0.037 | HMG CoA synthase inhibitor |
| 4 | 0.603 | 0.002 | Cholesterol synthesis inhibitor | 11 | 0.262 | 0.160 | Lipid metabolism regulator |
| 5 | 0.621 | 0.024 | Lipoprotein lipase inhibitor | 12 | 0.066 | 0.005 | HMG CoA reductase inhibitor |
| 6 | 0.592 | 0.024 | Hypolipemic | 13 | 0.242 | 0.240 | Insulin promoter |
| 7 | 0.417 | 0.005 | | | | | Anti-hyperlipoproteinemic |

4. Conclusion

Since plants and animals are essential sources of micronutrients for human beings and become toxic when consumed at higher level. So it necessary to monitor the levels in biological materials that are required by humans for both dietary and medicinal purposes (Kofi Annan *et al.*, 2010 and S. Gajalakshmi *et al.*, 2012) [6, 3]. The present study result showed that the PHF not contains high toxic level of any tested heavy

metals such as Arsenic, Chromium and Lead and is safe for the administration into the body.

GC-MS analysis isolates the six different compounds of medicinal importance from the methanol extract of the PHF. Prediction of biological activity of these compounds by using the PASS software was given an idea about the various possible activities of the isolated compounds; more importantly in the case of diabetes mellitus and related

complications. However, PASS is not being able to give an accurate prediction as they are based on two-dimensional (2D) structure of the molecule and does not calculate the molecular energy levels. Hence, it is necessary to confirm with further *in vitro* and *in vivo* studies.

5. Reference

1. Dembitsky VM, Glorizova TA, Poroikov VV. Novel anti-tumor agents: Marine sponge alkaloids, their synthetic analogs and derivatives. *Mini Rev Med Chem* 2005; 5:319-36.
2. Filimonov DA, Poroikov VV. Probabilistic approach in activity prediction. In: Varnek A, Tropsha A, editors. *Cheminformatics approaches to virtual screening*. Cambridge: RSC Publishing, 2008, 182-216.
3. Gajalakshmi S, Iswarya V, Ashwini R, Divya G, Mythili S, Sathivelu A. Evaluation of heavy metals in medicinal plants growing in Vellore District. *European Journal of Experimental Biology*. 2012; 2(5):1457-1461.
4. Glorizova TA, Filimonov DA, Lagunin AA, Poroikov VV. Evaluation of computer system for prediction of biological activity PASS on the set of new chemical compounds. *Chim. Pharm. J. (Rus)* 1998; 32(12):32-39.
5. Kadir MF, Bin Sayeed MS, Mia MM. Ethno pharmacological survey of medicinal plants used by traditional healers in Bangladesh for gastrointestinal disorders. *Journal of Ethno pharmacology* 2013; 147:148-156.
6. Kofi Annan, Asante IK, Asare C, Asare-Nkansah S, Bayor MT. Profile of heavy metals in some medicinal plants from Ghana commonly used as components of herbal formulations. *Pharmacognosy Res* 2010; 2(1):41-44.
7. Marwaha A, Goel RK, Mahajan MP. PASS-predicted design, synthesis and biological evaluation of cyclic nitrones as nootropics. *Bioorg Med Chem Lett* 2007; 17:5251-5.
8. Mohammad R, Reza F, Mojib SB. Effects of heavy metals on the medicinal plant. *International journal of Agronomy and Plant Production*, 2012, 3(4):154-158.
9. Murugesan A, Shanmugam R. GC-MS Analysis of Bioactive components of *Cordia alliodora* (Boraginaceae). *Hygeia: journal for drugs and medicines*; April 2014; 6(1):12-19
10. Poroikov VV, Filimonov D. Abstr. XVth Intern. Symp. Medicinal Chemistry, Bologna (Italy). 2000, 149.
11. Poroikov VV, Filimonov DA, Glorizova TA, Lagunin AA, Druzhilovsky DS, Stepanchikova AV. Computer-aided prediction of biological activity spectra for substances: Virtual chemogenomics. *Herald Vavilov Soc Genet Breed Sci* 2009; 13:137-43.
12. Stepanchikova AV, Lagunin AA, Filimonov DA, Poroikov VV. Prediction of Biological activity spectra for substances: Evaluation on the diverse sets of Drug-like structures. *Current Medicinal Chemistry*, 2003; 10:225-223.
13. Zotchev SB, Stepanchikova AV, Sergeyko AP, Sobolev BN, Filimonov DA, Poroikov VV. Rational design of macrolides by virtual screening of combinatorial libraries generated through *in silico* manipulation of polyketide synthases. *J Med Chem* 2006; 49:2077-87.
14. World Health Organization. WHO guidelines for assessing quality of herbal medicines with reference to contaminants and residues. World Health Organization Geneva 27, Switzerland, 2007.